Cardiff Oncology posts results for terminated onvansertib pancreatic cancer trial
The Phase 2 trial combining onvansertib with chemotherapy in metastatic pancreatic cancer was stopped early for enrollment and data reasons, with results posted on November 4, 2026.
Cardiff Oncology's registry record for NCT04752696 was updated with results posted on 2026-11-04.
- Onvansertib plus nanoliposomal irinotecan, leucovorin, and fluorouracil was tested in a Phase 2 trial for second-line treatment of metastatic pancreatic ductal adenocarcinoma. The study was terminated based on a sponsor decision after meeting essential enrollment and obtaining substantial data to support future pancreatic ductal adenocarcinoma trials in a first-line setting.1 The trial enrolled 41 participants (actual).1 Primary completion and study completion were both 2024-12-24 (actual).1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.